SHC - Sotera Health Company

Sotera Health provides Sterigenics ethylene oxide sterilization services, Nordion cobalt-60 gamma irradiation sources, and Nelson Labs laboratory testing and advisory services to medical device manufacturers, pharmaceutical companies, and food producers. The business model is B2B contract services, with customers paying for outsourced sterilization and microbial testing on a per-batch or long-term contract basis. Annual revenue is approximately $1.1B, with operations spanning North America, Europe, and select Asia-Pacific markets. Sterigenics sterilization services represent the largest revenue segment, serving hospitals and device makers who require regulatory-compliant sterilization for single-use medical products.

Past Year Trends

• Sotera Health grew FY2024 revenue 4.9% YoY to $1.10 billion while reducing net leverage from 3.8x to 3.7x, but Q4 2024 revenue declined 6.5% YoY to $290 million, signaling late-year customer timing weakness in the Sterigenics and Nelson Labs segments. (Neutral)
• Sterigenics settled 226 combined ethylene oxide personal-injury claims in two tranches during 2025 (97 claims for $30.9 million in April and 129 claims for $34 million in July), bringing total EtO litigation settlements since 2023 to approximately $472 million, while five additional Illinois claims remained set for trial in October 2025. (Bearish)
• Nordion secured a 25-year Class 1B operating license renewal from the Canadian Nuclear Safety Commission for its Ottawa cobalt-60 production facility—the longest such license ever granted by the CNSC—eliminating a major regulatory cliff risk for the global cobalt isotope supply underpinning Sotera's gamma sterilization business. (Bullish)

Next Year Trends

• Sotera's 2026 guidance calls for $1.233–$1.251 billion in revenue (5.0–6.5% constant currency growth) and $632–$641 million in adjusted EBITDA (5.5–7.0% growth), supported by $175–$225 million in capital expenditures for new Sterigenics capacity, though the new facility is not expected to contribute meaningfully until 2027, limiting near-term upside. (Neutral)
• The October 2025 Illinois EtO trial of five remaining Sterigenics claims will set a public damages benchmark that could drive additional settlement demands or adverse verdicts in pending Georgia and California cases, representing a headline litigation risk that could require further capital allocation away from deleveraging. (Bearish)
• Sotera refinanced $1.42 billion in term loans in May 2026 at a reduced spread of SOFR+2.25% (down 25 bps) with maturity extended to May 2031, reducing near-term refinancing risk, and the company's net leverage trajectory of 3.7x→3.3x through 2025 puts it on track to enter its 2.0x–3.0x long-term target range by 2026–2027, potentially unlocking capital return optionality. (Bullish)

Red Flags

[Securities Fraud / Investigation] Securities fraud class action lawsuit filed January 24, 2023 (U.S. District Court, N.D. Ohio) against Sotera Health Company and named executives, alleging the company concealed inadequate emissions controls at sterilization facilities that allowed dangerous ethylene oxide (EtO) emissions to pollute surrounding communities in violation of federal securities disclosure laws. — Levi & Korsinsky LLP / Bernstein Litowitz Berger & Grossmann LLP (plaintiff firms); case docket N.D. Ohio 2023, January 2023